Conformis announced that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA that resolves all patent disputes between the companies. Under the terms of the settlement, Medacta will receive a non-exclusive license to certain Conformis patents related to patient-specific instrumentation for use with off-the-shelf knee and shoulder implants.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CFMS:
- Conformis, Inc. Announces Settlement of Medacta Patent Litigation
- Conformis price target raised to $8.00 from $1.25 at Oppenheimer
- Conformis effects 1-for-25 reverse stock split
- Conformis Reports Third Quarter 2022 Financial Results
- Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022